India’s air quality challenge is no longer a seasonal concern. It is a persistent public health issue that touches families, cities and insurers alike. As claims linked to respiratory and cardiac ...

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its ...

The study also reported that interventions using a multifocal approach with evidence-based strategies to address clinical, ...

Lungpacer Medical, a leader in innovative respiratory care neurostimulation technologies, today announced that physicians at one of the nation's largest healthcare providers and top hospitals has ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, ...

Lungpacer Medical announced today that physicians performed the first commercial procedures using its FDA-cleared AeroPace ...

Good morning, everyone, and welcome to Ligand's 2025 Investor Day. I'm Melanie Herman, Head of Investor Relations for Ligand. And on behalf of our entire team, I'd like to thank you for taking the ...

Doctors treating seriously ill patients in an emergency setting may want to give the sedative etomidate, rather than ketamine ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investi ...

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel ...